Skip to main content

Table 2 Efficacy outcomes.

From: Effectiveness and safety of HAART regimens containing tenofovir DF + saquinavir or fosamprenavir in HIV patients: sub-analysis from PROTECTION study

 

FPV Cohort (n = 105)

SQV Cohort (n = 98)

% viral failure

22%

13%

Mean time of follow-up (months)

10.5

9.6

Mean CD4 count increase*

+84 cells/mm3

+12 cells/mm3

  1. *In those subjects with 48 week data available (n = 36 and 26 for FPV and SQV cohorts, respectively).
Back to article page

Journal of the International AIDS Society

ISSN: 1758-2652